Alta Sciences

APRIL 17, 2024

In this blog article, we review some of these areas of investigation where Altasciences has robust expertise and solution offerings. According to a 2022 article published in Molecular Psychiatry, treatment resistance affects 20 to 60% of patients with psychiatric disorders. Asia, and Europe.

Drug Development 52

Drug Development Treatment Drugs FDA Approval 52

Codon

JUNE 11, 2024

Sign up to get articles from Asimov Press. Their solution was to fuse hairpins, little loops made from RNA or DNA, at various positions along the DNA strand that was being sequenced. As the DNA passed through a nanopore, these hairpins would get stuck inside the nanopore and slow down the DNA’s movement.

DNA 96

DNA Engineering RNA Small Molecule 96

Drug Target Review

JULY 11, 2023

In this article, I spoke to Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, about how AI is transforming the landscape of disease research, unlocking a treasure trove of knowledge that may hold the key to a healthier future. Cavlan will explore more of these ends in our next article.

Disease 75

Disease RNA Small Molecule Clinical Development 75

Codon

APRIL 2, 2023

This is Codon Digest, a weekly roundup of research papers, news articles, and industry highlights about engineered biology. Read A new DNA polymerase variant, called RT-KTq I614Y, can directly detect RNA modifications, including pseudouridine (Ψ) and queuosine (Q). Massively parallel profiling of RNA-targeting CRISPR-Cas13d.

DNA 52

DNA RNA Engineering Licensing 52

Codon

APRIL 30, 2023

Read Ribosomes are able to build proteins because they contain a strand of RNA that imbues them with their catalytic power. Read An automated platform to make riboswitches (RNA strands that bind to small molecules and then quickly switch their structure) that can sense specific proteins. Synthetic Biology. Cell Systems.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Read Ribosomes are able to build proteins because they contain a strand of RNA that imbues them with their catalytic power. Read An automated platform to make riboswitches (RNA strands that bind to small molecules and then quickly switch their structure) that can sense specific proteins. Synthetic Biology. Cell Systems.

Vaccine 52

Vaccine DNA Engineering RNA 52

KIF1A

AUGUST 20, 2024

Susannah’s ASO Treatment Regimen A brief note: Throughout this post I will be citing the original article; unless otherwise noted, quotes are sourced from Ziegler et al. The effects of an ASO administered to the eye have yet to be determined, and we are also investigating small-molecule therapies to treat this high-priority symptom.

Science 52

Science Treatment Therapies Small Molecule 52

Codon

DECEMBER 12, 2024

” The report accompanies an article in Science , also released today, entitled “Confronting Risks of Mirror Life.” For the article in Science , more than 30 scientists from ten countries are calling on the broader community to confront the risks of mirrored life. ” But what, exactly, is a mirrored organism?

RNA 104

RNA DNA Vaccine Virus 104

Codon

APRIL 16, 2023

Read There’s a news article that breaks down this work. Read An RNA-based system to study hepatitis B virus replication and evaluate antivirals. Read [Comment] Delivering the next generation of cancer immunotherapies with RNA. Comparison of transformations for single-cell RNA-seq data. Favate J.S. Debès C.

Engineering 52

Engineering DNA RNA Science 52

Codon

FEBRUARY 16, 2025

This article is best experienced on our website. Building a Circuit Much like electronic circuits, which use wires and transistors to create or process signals, a synthetic gene circuit is a network of biological parts — DNA, RNA, and proteins — that process inputs and generate outputs. 3 Subscribe to Asimov Press.

DNA 93

DNA RNA Engineering Small Molecule 93

Drug Target Review

FEBRUARY 4, 2025

In this article, we spoke with Fiona Elwood, PhD, Vice President and Disease Area Stronghold Leader for Neurodegeneration at Johnson & Johnson. Were diversifying our portfolio beyond tau to other targets and molecules that could be dosed alone or even in the future as part of combinations, Elwood reveals.

FDA 59

FDA Drugs Disease Science 59